FULC
Companies
NASDAQ
Fulcrum Therapeutics Inc.
Health Care
$7.00
+$2.30 (+48.83%)
Price Chart
Overview
About FULC
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Market Cap
$515.3M
Volume
5.1M
Avg. Volume
4.7M
P/E Ratio
-5.336066
Dividend Yield
0.00%
Employees
100.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.56
High Correlation
Volatility
High (0.91)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, FULC shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$515.3M
Volume5.1M
P/E Ratio-5.34
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 1, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025